Form 10-Q HALOZYME THERAPEUTICS For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall St futures edge up as Hormuz progress weighs down oil prices
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
Halozyme Therapeutics (HALO) PT Raised to $21 at BMO Capital
August 8, 2018 6:59 AM EDTBMO Capital raised its price target on Halozyme Therapeutics (NASDAQ: HALO) to $21.00 (from $19.00) while maintaining a Market Perform rating.
Analsyt Do Kim commented, "We raise our target to $21 from $19, as our probability of success for PEGPH20 in pancreatic cancer increases to 70% from 65%, following positive... More
